

(Gly14)-Humanin (human)

Cat. No.:	HY-P3993
CAS No.:	330936-70-4
Molecular Formula:	C ₁₁₈ H ₂₀₂ N ₃₄ O ₃₁ S ₂
Molecular Weight:	2657.21
Sequence Shortening:	MAPRGFSCLLLLTGEIDLPKRRA
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	(Gly14)-Humanin (human) (14-Glycine-Humanin (human)) is an analog of Humanin in which the 14th amino acid serine was replaced with glycine (Gly). (Gly14)-Humanin (human) has anti-apoptotic and neuroprotective functions ^{[1][2]} .																
In Vitro	<p>(Gly14)-Humanin (human) (0.1-10 μM; 72 hours) significantly increases cell viability, reduced nuclear fluorescence of HUVECs, the levels of cleaved PARP, ROS formation and the ratio of bax/bcl-2 compared with treatment with high glucose (HG) for 72h. And reduces mRNA level of bax and increases mRNA level of bcl-2^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human umbilical vein endothelial cells (HUVECs)</td> </tr> <tr> <td>Concentration:</td> <td>100 nM, 1 μM and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>Pretreatment 3 hours and then treated with 72 hours</td> </tr> <tr> <td>Result:</td> <td>Significantly increased cell viability.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human umbilical vein endothelial cells (HUVECs)</td> </tr> <tr> <td>Concentration:</td> <td>1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>Pretreatment 3 hours and then treated with 72 hours</td> </tr> <tr> <td>Result:</td> <td>Reduced the ratio of bax/bcl-2.</td> </tr> </table>	Cell Line:	Human umbilical vein endothelial cells (HUVECs)	Concentration:	100 nM, 1 μM and 10 μM	Incubation Time:	Pretreatment 3 hours and then treated with 72 hours	Result:	Significantly increased cell viability.	Cell Line:	Human umbilical vein endothelial cells (HUVECs)	Concentration:	1 μM	Incubation Time:	Pretreatment 3 hours and then treated with 72 hours	Result:	Reduced the ratio of bax/bcl-2.
Cell Line:	Human umbilical vein endothelial cells (HUVECs)																
Concentration:	100 nM, 1 μM and 10 μM																
Incubation Time:	Pretreatment 3 hours and then treated with 72 hours																
Result:	Significantly increased cell viability.																
Cell Line:	Human umbilical vein endothelial cells (HUVECs)																
Concentration:	1 μM																
Incubation Time:	Pretreatment 3 hours and then treated with 72 hours																
Result:	Reduced the ratio of bax/bcl-2.																
In Vivo	<p>(Gly14)-Humanin (human) (0.1 μg/5 μL; i.c.v.; once) decreases cells with plasmalemma permeability in the injured cortex and hippocampus, reduces brain lesion volume, improves motor performance and ameliorates performance in the Morris water maze test^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult male CD-1 mice (25-30 g; 10-12-week-old) bearing traumatic brain injury (TBI)^[2]</td> </tr> </table>	Animal Model:	Adult male CD-1 mice (25-30 g; 10-12-week-old) bearing traumatic brain injury (TBI) ^[2]														
Animal Model:	Adult male CD-1 mice (25-30 g; 10-12-week-old) bearing traumatic brain injury (TBI) ^[2]																

Dosage:	0.1 µg/5 µL
Administration:	Intracerebroventricularly (i.c.v.); once
Result:	Decreased cells with plasmalemma permeability in the injured cortex and hippocampus, reduced brain lesion volume, improved motor performance.

REFERENCES

- [1]. Ying Xie, et al. Protection effect of [Gly14]-Humanin from apoptosis induced by high glucose in human umbilical vein endothelial cells. *Diabetes Res Clin Pract.* 2014 Dec;106(3):560-6.
- [2]. T Wang, et al. [Gly14]-Humanin reduces histopathology and improves functional outcome after traumatic brain injury in mice. *Neuroscience.* 2013 Feb 12;231:70-81.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA